-
摘要:
目的 评估循环肿瘤细胞（circulating tumor cell，CTC）在预测乳腺癌患者预后中的作用。 方法 检索Medline、Embase、中国数字化期刊全文数据库（CNKI）、万方数据库及维普全文网中国内外相关文献，收集检测外周血肿瘤细胞在乳腺癌患者预后中的研究，使用Review Manager 5.1.4中的方差倒数法对无进展生存期（progression-free survival，PFS）和总生存期（overall survival，OS）进行Meta分析。 结果 共纳入33篇英文文献，总计5 393例乳腺癌患者。Meta分析结果提示CTC阳性组较CTC阴性组在PFS [HR=2.09（95%CI：1.72~2.55），n=23，I2=57%]和OS[HR=2.49（95%CI：2.18~2.85），n=24，I2=0]方面差异均有统计学意义（P < 0.01）。根据UICC（International Union Against Cancer）肿瘤分期进行亚组分析，结果显示CTC对不同期别肿瘤的PFS和OS也均有预测价值（P < 0.01）。 结论 外周血CTC阳性的乳腺癌患者与CTC阴性患者相比预后较差，CTC可以作为乳腺癌患者的预后预测指标。 Abstract:Objective To assess the role of detecting circulating tumor cells (CTCs) in predicting the prognosis of breast cancer patients. Methods Clinical trials that assessed the prognostic relevance of tumor cell detection in the peripheral blood of breast cancer patients were retrieved from MEDLINE, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP information database. The generic inverse variance in Review Manager 5.1.4 was used for meta-analysis and the main parameters included progression-free survival (PFS) and overall survival (OS). Results A total of 33 studies including 5, 393 patients were eligible for final analyses. Meta-analyses associated the presence of CTCs with both poor PFS [HR = 2.09 (95% CI: 1.72 to 2.55), n = 23, I2 = 57%] and OS [HR = 2.49 (95% CI: 2.18 to 2.85), n = 24, I2 = 0%]. The subgroup analysis by the International Union Against Cancer Staging showed that CTCs was a statistically significant prognostic factor of stages I to III and stage IV breast cancer patients (P < 0.00001). Conclusion The presence of CTCs indicates early recurrence and death in patients with breast cancer, and the detection of CTCs can be used to predict prognosis of breast cancer patients. -
Key words:
- Circulating tumor cells /
- Breast cancer /
- Prognosis /
- Progression-free survival /
- Overall survival
-
图 3 CTC与PFS（A）和OS（B）关系
CTC：循环肿瘤细胞；PFS：无进展生存期；OS：总生存期
Figure 3. Correlation of CTS with PFS (A) and OS (B) of breast cancer patients
-
[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.20107 [2] Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators[J]. JAMA, 1994, 271(20): 1587-1592. [3] Ashworth TR, A case of cancer in which cells similar to those in the tumors were seen in the blood after death[J]. Aust Med J, 1869, 14: 146-149. http://www.mendeley.com/catalog/case-cancer-cells-similar-those-tumors-were-seen-blood-after-death/ [4] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8(6): 1-16. http://eprints.ucl.ac.uk/1304945/1/1745-6215-8-16.pdf [5] Molloy TJ, Bosma AJ, Baumbusch LO, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients[J]. Breast Cancer Res, 2011, 13(3): R61. doi: 10.1186/bcr2898 [6] Bidard FC, Mathiot C, Delaloge S, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer[J]. Ann Oncol, 2010, 21(4): 729-733. doi: 10.1093/annonc/mdp391 [7] Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer[J]. Gastroenterology, 2010, 138(5): 1714-1726. doi: 10.1053/j.gastro.2010.01.008 [8] Hayashi N, Nakamura S, Tokuda Y, et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer[J]. Int J Clin Oncol, 2011, doi: 10.1007/s1014z7-011-0260-0[Epubaheadofprint]. [9] De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and[18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer[J]. J Clin Oncol, 2009, 27(20): 3303-3311. doi: 10.1200/JCO.2008.19.4423 [10] Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer[J]. J Clin Oncol, 2005, 23(7): 1420-1430. doi: 10.1200/JCO.2005.08.140 [11] Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer[J]. J Clin Oncol, 2009, 27(13): 2177-2184. doi: 10.1200/JCO.2008.18.0497 [12] Daskalaki A, Agelaki S, Perraki M, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer[J]. Br J Cancer, 2009, 101(4): 589-597. doi: 10.1038/sj.bjc.6605183 [13] Apostolaki S, Perraki M, Kallergi G, et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance [J]. Breast Cancer Res Treat, 2009, 117(3): 525-534. doi: 10.1007/s10549-008-0239-3 [14] Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer[J]. Br J Cancer, 2006, 94(5): 672-680. doi: 10.1038/sj.bjc.6602985 [15] Lang JE, Hall CS, Singh B, et al. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?[J]. Expert Rev Anticancer Ther, 2007, 7(10): 1463-1472 doi: 10.1586/14737140.7.10.1463 [16] Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients[J]. Clin Cancer Res, 2004, 10(4): 1392-1400. doi: 10.1158/1078-0432.CCR-0102-03 -
下载:
点击查看大图
图(4)
计量
- 文章访问数: 37
- HTML全文浏览量: 3
- PDF下载量: 3
- 被引次数: 0
